Skip to content

Randomized Controlled Study of Xianhe Decoction on Perioperative Coagulation Function in Total Knee Arthroplasty for Hemophilic Arthropathy

Randomized Controlled Study on the Effect of Xianhe Decoction on Perioperative Coagulation Function in Total Knee Arthroplasty for Hemophilic Arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001742
Enrollment
Unknown
Registered
2026-07-16
Start date
2026-07-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilic Arthropathy

Interventions

Control Group:Routine coagulation factor replacement therapy.
Treatment group:Oral Crane Decoction combined with routine coagulation factor replacement therapy.

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1. Age 18–65 years, with a confirmed diagnosis of Hemophilia A; 2. Meets the Western diagnostic criteria for hemophilic arthropathy and is classified as having Kidney Deficiency and Marrow Deficiency according to traditional Chinese medicine (TCM) differentiation; 3. Imaging assessment meets the Amold-Hilgartner grading criteria at = Grade IV; 4. Clearly intends to undergo unilateral total knee arthroplasty; 5. Negative for inhibitors; 6. Able to accept TCM intervention and provides informed consent before the procedure; 7. Hemoglobin =90 g/L, with essentially normal liver and kidney function.

Exclusion criteria

Exclusion criteria: 1. Coexisting conditions causing knee joint lesions (e.g., rheumatoid arthritis, gout); 2. Presence of high-titer FVIII inhibitors; 3. Coexisting severe dysfunction of major organs such as heart, liver, and kidneys; 4. Inability to receive regular Chinese herbal treatment post-surgery; 5. History of allergy to components of Xianhe Decoction or severe gastrointestinal discomfort; 6. Participation in other interventional clinical studies.

Design outcomes

Primary

MeasureTime frame
Coagulation Factor Activity;

Secondary

MeasureTime frame
Intraoperative blood loss;Postoperative drainage volume;Postoperative hemoglobin decline value;Total preoperative factor dose;Incidence of complications;Cumulative Factor Usage;The time for post-operation adjustment to rehabilitation dosage.;

Countries

China

Contacts

Public ContactShuaijie Lv

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

939585937@qq.com13656670181

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026